Reward summation and the effects of dopamine D1 and D2 agonists and antagonists on fixed-interval responding for brain stimulation

https://doi.org/10.1016/0091-3057(94)90192-9Get rights and content

Abstract

The effects of dopamine D1 and D2 agonists and antagonists on fixed-interval (FI) self-stimulation were investigated using a reward-summation model, trading off frequency with train duration. The D1 antagonist SCH 23390 (0.005–0.02 mg/kg) decreased FI self-stimulation and the inhibition was reversed by increasing stimulation frequency. Moreover, amphetamine (0.5 mg/kg) reversed the inhibition by a low dose of SCH 23390 (0.005 mg/kg) but not after a higher dose inhibition could not be dissociated from a performance deficit. There was no significant interaction between low doses of spiperone and SCH 23390 when coadministered that could not be predicted from their effects when given individually. Self-stimulation was inhibited by the D1 agonist SKF 38393 (5 mg/kg). When coadministered with amphetamine, SKF 38393 partially blocked amphetamine's facilitation. The D2 agonist bromocriptine (10 mg/kg) produced an extraordinary enhancement of performance that was also evident after a lower dose (5 mg/kg) when it was combined with amphetmaine. This enhancement of performance showed little extinction when stimulation was no longer available, suggesting it was a novel form of stereotypy. These results support the concept that D1 dopamine receptors play a critical role in modulating the reinforcing consequences of lateral hypothalamic stimulation. The involvement of D2 receptors on reinforcement processes remains contentious due to their effects on performance and insensitivity of responding to coincide with changes in reinforcement magnitude.

References (58)

  • J. Hyttel

    SCH 23390—the first selective dopamine D−1 antagonist

    Eur. J. Pharmacol.

    (1983)
  • G.F. Koob et al.

    The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat

    Neurosci. Lett.

    (1987)
  • P.M. Laduron et al.

    Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity

    Biochem. Pharmacol.

    (1979)
  • N.J. Leith

    Effects of apomorphine on self-stimulation responding: Does the drug mimic the current?

    Brain Res.

    (1983)
  • P. Leone et al.

    Blockade of D−1 receptors bu SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning

    Eur. J. Pharmacol.

    (1987)
  • J.M. Liebman

    Discriminating between reward and performance: A critical review of intracranial self-stimulation methodology

    Neurosci. Biobehav. Rev.

    (1983)
  • R. Miller et al.

    Dopamine D-1 and D-2 receptors in relation to reward and performance: A case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs

    Prog. Neurobiol.

    (1990)
  • S. Nakajima et al.

    Reduction of the rewarding effect of brain stimulation by a blockade of dopamine D1 receptor with SCH 23390

    Pharmacol. Biochem. Behav.

    (1986)
  • P.-P. Rompré et al.

    GBR 12909 reverses the SCH 23390 inhibition of rewarding effects of brain stimulation

    Eur. J. Pharmacol.

    (1990)
  • G.J. Schaefer et al.

    Schedule-controlled brain self-stimulation: Has it utility for behavioral pharmacology?

    Neurosci. Biobehav. Rev.

    (1992)
  • P.E. Setler et al.

    The central effects of a novel dopamine agonist

    Eur. J. Pharmacol.

    (1978)
  • A. Wauquier

    Neuroleptics and brain self-stimulation behavior

    Int. Rev. Neurobiol.

    (1979)
  • R.A. Wise

    Catecholamine theories of reward: A critical review

    Brain Res.

    (1978)
  • D.M. Atrens

    Self-stimulation and psychotropic drugs: A methodological and conceptual critique

  • R.J. Beninger et al.

    Effects of extinction, pimozide, SCH 23390, and metaclopramide on food-rewarded operant responding of rats

    Psychopharmacology (Berlin)

    (1987)
  • C.L.E. Broekkamp et al.

    Effects of apomorphine on self-stimulation behavior

    Psychopharmacologia

    (1974)
  • D.K. Clark et al.

    Review: D1 dopamine receptor—the search for a function: A critical evaluation of the D1D2 dopamine receptor classification and its functional implications

    Synapse

    (1987)
  • D. Coulombe et al.

    Fitting intracranial self-stimulation data with growth models

    Behav. Neurosci.

    (1987)
  • S. Degelmann et al.

    Acute and chronic effects of psychoactive drugs on PFC self-stimulation

    Soc. Neurosci. Abstr.

    (1986)
  • Cited by (25)

    • Differential effects of dopamine receptor subtype-specific agonists with respect to operant behavior maintained on a differential reinforcement of low-rate responding (DRL) schedule

      2015, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      Moreover, if we take the null result of PD168077 on DRL behavior into account, it is clear that the operant behavior task used in the present study can be used to screen drugs classified as selective DA receptor agonists. Furthermore, as observed in several other types of behavioral measurement with respect to psychopharmacology, the effects of direct/selective DA receptor agonist are known to be different to those of amphetamine; specifically, the operant responding to conditioned reward (Sutton and Benninger, 1999), to risk-based decision making (St. Onge and Floresco, 2009), and to intracranial self-stimulation (Baldo et al., 1999; Hunt et al., 1994). In addition, it is interesting to point out that the peak time measured in this study was unaffected by any of the tested DA receptor agonists.

    • Prenatal Exposure to Cocaine Increases the Rewarding Potency of Cocaine and Selective Dopaminergic Agonists in Adult Mice

      2008, Biological Psychiatry
      Citation Excerpt :

      Although most investigators agree that BSR threshold is elevated by systemic administration of the selective D1 antagonist SCH-23390, findings are inconsistent among the few studies that have examined the effect of systemically-administered D1 agonists on ICSS. Reports have shown decreased ICSS after SKF-38393 administration in a reward-summation procedure (44) and increased BSR threshold after SKF-81297 administration with a rate-independent method (45), whereas others have shown decreased BSR threshold with SKF-38393 (46) and A-77636 (47) with the curve-shift method that we employ. We previously demonstrated in Swiss-Webster mice that systemic administration of SKF-82958 lowers BSR threshold in a dose-dependent manner (31).

    • Decreased sensitivity to the effects of dopamine D1-like, but not D2-like, receptor antagonism in the posterior hypothalamic region/anterior ventral tegmental area on brain reward function during chronic exposure to nicotine in rats

      2005, Brain Research
      Citation Excerpt :

      Evidence indicates that D1-like receptors play a pivotal role in the reinforcing effects of ICSS. For example, prior research showed that SCH 23390 administered systemically decreased the reinforcing effects of ICSS [3,19,22,50]. Conversely, treatment with the D1-like receptor agonists SKF 38393 and A-77636 has been shown to potentiate brain reward function as assessed with the ICSS procedure [47,59].

    View all citing articles on Scopus
    2

    Present address: Research Laboratories, Astra Alab AB, Södertäje, Sweden

    View full text